<DOC>
	<DOCNO>NCT02873806</DOCNO>
	<brief_summary>The study objective evaluate intraocular pressure ( IOP ) lower effect two iStent device eye subject primary open-angle glaucoma , wash two anti-glaucoma medication ( one Prostaglandin ) prior stent implantation .</brief_summary>
	<brief_title>Two Trabecular Micro-bypass Stents &amp; Postoperative Travoprost Treat Glaucoma Subjects Two Hypotensive Agents</brief_title>
	<detailed_description>The study design follow : - Prospective , single-arm study . - Subjects open-angle glaucoma medicate IOP &gt; 18 mmHg ≤ 30 mmHg . - Subjects two topical ocular hypotensive medication ( one prostaglandin ) . - Implantation two iStent inject device ( IOP &lt; 6 mmHg , point postoperative follow-up , medication prescribe discontinue ) . - IOP measure two ( 2 ) observer minimize bias ; observer 1 look slit lamp turn dial reading mask , observer 2 document IOP . - Follow-up 60 month postoperative ( 61 month subject need undergo terminal washout ) . - Descriptive statistic tabulate . - Medical therapy consider necessary subject 's welfare implement time study investigator 's discretion .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Screening Exam Phakic patient pseudophakic patient posterior chamber intraocular lens ( PCIOLs ) Primary openangle glaucoma ( include pigmentary pseudoexfoliative ) C/D ratio ≤ 0.9 Visual field defect , nerve abnormality characteristic glaucoma Two topical hypotensive medication time screen exam IOP &gt; 18 mmHg ≤ 30 mmHg ( medicate ) screen exam Study eye BCVA 20/100 good Normal angle anatomy determine gonioscopy Absence peripheral anterior synechia ( PAS ) , rubeosis angle abnormality could impair proper placement stent Baseline Exam Subject complete appropriate medication washout Mean IOP &gt; 22 mmHg ≤ 38 mmHg antiglaucoma medication washout period A 3mmHg IOP increase screen mean IOP Screening Exam Aphakic patient pseudophakic patient anterior chamber IOLs ( ACIOLs ) Prior stent implantation ( study eye ) Traumatic , uveitic , neovascular , angleclosure glaucoma ; glaucoma associate vascular disorder Functionally significant visual field loss , include severe nerve fiber bundle defect Prior incisional glaucoma surgery Prior SLT within 90 day prior screen Prior ALT Iridectomy laser iridotomy Ineligibility ocular hypotensive medication washout period determine investigator . Any active corneal inflammation edema ( e.g. , keratitis , keratoconjunctivitis , keratouveitis ) Clinically significant corneal dystrophy ( e.g. , bullous keratopathy , Fuch 's dystrophy ) ; guttata Corneal surgery ( prior anticipate ) type ( include LASIK , LASEK , PRK , etc . ) may interfere IOP measurement reliability Corneal opacity would inhibit visualization nasal angle Congenital traumatic cataract Retinal optic nerve disorder associate exist glaucoma condition Elevated episcleral venous pressure associate : active thyroid orbitopathy ; cavernous sinus fistula ; SturgeWeber syndrome ; orbital tumor ; orbital congestive disease Clinically significant sequela trauma Chronic ocular inflammatory disease presence active ocular inflammation Baseline Exam Subject complete medication washout Mean IOP &lt; 22 mmHg &gt; 38 mmHg antiglaucoma medication washout Subject 3mmHg IOP increase screen mean diurnal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>